148054-65-3

Basic information

• Product Name: (S)-ALPHA-PHENYL-1-PIPERIDINEETHANAMINE
• Synonyms: (S)-ALPHA-PHENYL-1-PIPERIDINEETHANAMINE;(S)-a-Phenyl-1-piperidineethanamine 2HCl
• CAS NO: 148054-65-3
• Molecular Formula: C₁₃H₂₀N₂
• Molecular Weight: 204.31
• Mol File: 148054-65-3.mol

Chemical Properties

• Boiling Point: 313.0±22.0 °C(Predicted)
• Appearance: /
• Density: 1.020±0.06 g/cm3(Predicted)
• PKA: 10.47±0.10(Predicted)
• CAS DataBase Reference: (S)-ALPHA-PHENYL-1-PIPERIDINEETHANAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-ALPHA-PHENYL-1-PIPERIDINEETHANAMINE(148054-65-3)
• EPA Substance Registry System: (S)-ALPHA-PHENYL-1-PIPERIDINEETHANAMINE(148054-65-3)

Safety Data

• Hazardous Substances Data: 148054-65-3(Hazardous Substances Data)

Upstream product

• 889864-59-9 (S)-2-Amino-2-phenyl-1-piperidin-1-yl-ethanone 
• 7101-04-4 (E/Z)-1-(2-hydroximino-2-phenylethyl)piperidine 
• 110-89-4 piperidine 
• 117049-14-6 tert-butyl N-[(1S)-2-hydroxy-1-phenylethyl]carbamate 
• 20989-17-7 (2S)-2-phenylglycinol 
• 110143-62-9 (S)-(+)-<2-<(methylsulfonyl)oxy>-1-phenylethyl>carbamic acid 1,1-dimethylethyl ester 
• 5491-18-9 (S)-N-(benzyloxycarbonyl)phenylglycine 
• 136412-37-8 ((S)-2-Oxo-1-phenyl-2-piperidin-1-yl-ethyl)-carbamic acid benzyl ester 
• 83829-03-2 (S)-1-phenyl-2-(piperidin-1-yl)ethan-1-ol 
• 154472-05-6 (2R)-(-)-2-phenyl-2-(piperidin-1-yl)ethanol 
• 20780-54-5 (S)-styrene oxide 

Downstream Products

• 148076-28-2 Methyl-[((S)-2-oxo-1-phenyl-2-piperidin-1-yl-ethylcarbamoyl)-methyl]-carbamic acid benzyl ester 
• 1039631-76-9 N-(tert-butoxycarbonyl)-3-(S)-(1-(S)-phenyl-2-N'-piperidinylethyl)aminopyrrolidine 
• 1629873-34-2 (S)-N-benzhydryl-1-phenyl-2-(piperidin-1-yl)ethanamine 

Relevant articles and documents

COMPOUNDS WHICH INHIBIT THE GLYCINE TRANSPORTER AND USES THEREOF

Compounds of formula (I) and salts and solvates are provided wherein R2 is selected from phenyl substituted with n R1 groups, and pyridyl substituted with n R1 groups; n = 0, 1 or 2; each R1 is independently selected from the group consisting of halo, C1-4alkyl, C1-4alkoxy, haloC1-4alkyl, haloC1-4alkoxy and cyano; R3 is selected from hydrogen and C1-2 alkyl; R4 is selected from the group consisting of ethyl, n- propyl, i-propyl, n-butyl, i-butyl and t-butyl; or R3 and R4 together with the nitrogen atom to which they are attached form a saturated 5- or 6-membered heterocyclic ring optionally substituted with one or more groups X; each X is independently selected from the group consisting of C1-4alkyl, and haloC1-4alkyl; R12 is selected from the group consisting of hydrogen, fluoro, chloro, bromo, methyl and methylthio; R13 is selected from hydrogen, chloro and trifluoromethyl; R14 is selected from hydrogen, trifluoromethyl and chloro; R15 is selected from hydrogen, chloro and trifluoromethyl; R16 is selected from hydrogen, methyl, fluoro and chloro; R12, R13, R14, R15 and R16 not all simultaneously being hydrogen. Processes for the preparation and uses of the compounds as medicaments for treating disorders such as psychoses, dementia or attention deficit disorder are also disclosed.

Dehydrogenation of cyclic tertiary amines with neighbouring of enantiomeric nucleophiles

For stereochemical investigation of their dehydrogenation, the enantiomers of the aminoalcohols 1, 2, and 3 were prepared from optically active sources, while the enantiomers of the diamines 8 and 9 were available by resolution of the racemates. The pure antipodes of 1, 2, and 3 reacted with mercury(II)-EDTA by a twofold dehydrogenation via intermediate participation of the neighbouring alcoholic group to the optically active lactams 5, 6, and 7 under complete retention of configuration. In the same manner the diamines 8 and 9 generated by four electron withdrawal the cycloamidines 10 and 11.

Benzoxazolamines and Benzothiazolamines: Potent, Enantioselective Inhibitors of Leukotriene Biosynthesis with a Novel Mechanism of Action

A series of benzoxazolamine and benzothiazolamine analogs that inhibit leukotriene (LT) biosynthesis are described.The initial lead, (S)-N-(benzothiazol-2-yl)phenylalanine ethyl ester (5a), was discovered in a screening program for inhibition of Ca-ionophore-A23187-induced LTB4 release in human polymorphonuclear leukocytes (IC50 0.23 μM).Through structural modification, it was determined that hydrophobic substituents in the 5-position and replacement of the phenyl ring of phenylalanine with a cyclohexyl group greatly enhance potency.Several ester bioisosteres that retain potency and enantiomeric selectivity are described.Lead optimization culminated in (S)-N--5-methyl-2-benzoxazolamine (43b), IC50 0.001 μM.The compounds described are not inhibitors of 5-lipoxygenase but, rather, act at the level of arachidonic acid release.

Enantioselective conjugate addition to cyclic enones with scalemic lithium organo(amido)cuprates, part IV. Relationship between ligand structure and enantioselectivity

Scalemic lithium amides derived from primary and secondary amines react with organocopper compounds in ether or dimethyl sulfide to form lithium organo(amido)cuprates capable of enantioselective conjugate addition to 2-cycloalkenones. The most successful heterocuprate, in which the chiral ligand is (S)-N-methyl-1-phenyl-2-(1-piperidinyl)ethanamine, (S)-MAPP, 13, reacts with cyclic enones to form products with up to 97% ee. Nonlinear asymmetric induction was observed with the cuprate formed from ligand 13.